Skip to main content
editorial
. 2016 Apr 29;10(5):702–726. doi: 10.1007/s12072-016-9717-6

Table 5.

All-oral treatment for treatment-experienced HCV genotype 3 in the Asian-Pacific Region

Companies (regimen) [references] Drug targets Ribavirin Duration of treatment (weeks) SVR (%)
NS5A NS5B
Gilead Sciences [68, 71] Sofosbuvir (400 mg daily) + 16 or 24 16 weeks
Non-cirrhotic: 63
F4: 61
24 weeks
Non-cirrhotic: 87
F4: 60